Replies to post #44062 on Biotech Values

[DewDiligence]

FOLD Completes IPO at $15/share

[They picked FOLD as the stock ticker because they claim to have expertise in protein folding, but that doesn’t mean it was a wise choice :-)]

http://yahoo.reuters.com/news/articlehybrid.aspx?storyID=urn:newsml:reuters.com:20070531:MTFH33964_2...

>>
Wed May 30, 2007 8:20pm ET

NEW YORK, May 30 (Reuters) - Biopharmaceutical firm Amicus Therapeutics on Wednesday raised $75 million in an initial public offering that priced within an expected forecast range.

The 5-million-share offering priced at $15 per share compared with a forecast range of $14 to $16.

Underwriters, led by Morgan Stanley and Merrill Lynch, have the option to purchase an additional 750,000 shares to cover overallotments.

Amicus plans to list its stock on the Nasdaq under the symbol FOLD .
<<